Key Takeaways
- Researchers at McMaster University found that Pseudomonas aeruginosa can temporarily evade phage attacks by entering a “stealth mode.”
- Phage steering is proposed as a potential avenue for treatment, allowing bacteria to become less harmful rather than entirely eliminated.
- The study highlights the resilience of bacteria against phage therapy and emphasizes the need for careful application in clinical settings.
Revealing Bacterial Resilience Against Phages
New research from McMaster University underscores the complex dynamics between bacteria and phages, the viruses that target them. As antimicrobial resistance (AMR) continues to challenge antibiotic efficacy, phages are emerging as a potential alternative. However, they are not invulnerable to bacterial resistance.
Pseudomonas aeruginosa, a notorious drug-resistant bacterium responsible for various infections, can evade phage attacks by entering what researchers call a “stealth mode.” This mechanism allows the bacteria to temporarily halt the production of pili—hair-like structures that facilitate infection and also serve as entry points for phages.
According to Professor Lori Burrows, the principal investigator of the study, while some phages exploit pili to infect and kill Pseudomonas, the bacteria can outsmart these viruses by stopping their pili production. Veronica Tran, a graduate student and first author of the paper, emphasizes that bacteria can evolve resistance to phages just as they do with antibiotics. Yet, in certain situations, this can be advantageous. If Pseudomonas disarms its pili in response to phage exposure, it may become less virulent.
The study introduces the concept of “phage steering,” where the objective is not to eradicate the bacteria entirely but to modify their behavior toward becoming less harmful. However, the findings reveal unexpected complexities. Out of 28 phage-resistant Pseudomonas mutants observed, one mutant exhibited an ability to regain full pili function once phages were removed from its environment. This process indicates that bacteria may possess temporary resistance and could return to a virulent state after treatment, raising concerns about recurring infections in clinical settings.
Burrows notes that these findings highlight the resourcefulness of bacteria and serve as a reminder that even promising phage therapies need careful management. Utilizing phages in cocktails may mitigate the risk of developing resistance, as it becomes increasingly difficult for bacteria to evade multiple phage types simultaneously.
Currently, phage therapies are not officially approved in Canada but may be prescribed on compassionate grounds for patients with life-threatening antibiotic-resistant infections. Two cases involving McMaster patients demonstrate the potential of phage therapy: one treated a severe joint infection caused by drug-resistant Staphylococcus epidermidis, and another resolved a chronic urinary tract infection.
Both instances solidify the notion that phages could serve as viable treatment options against drug-resistant infections. To prepare for a broader implementation of phage therapy in Canada, ongoing research is crucial. Understanding bacterial adaptation to phages will be essential to avoid a repeat of the resistance challenges faced with antibiotics.
The study sheds light on the importance of continued research into phage therapy, particularly as it gains traction as a therapeutic alternative amidst rising concerns of AMR.
The content above is a summary. For more details, see the source article.